Febuxostat can effectively reduce the risk of gout and hyperuricemia by stably controlling the patient's uric acid value.
Scope of the Report:Febuxostat is a uric acid production inhibitor. It is an activity that can hinder the production of blood uric acid in the body - xanthine oxidase. Then the body normally metabolizes excess uric acid from the body. Therefore, it will not increase the burden of liver and kidney, and patients with low liver and kidney function can also take this drug conveniently.
The worldwide market for Febuxostat is expected to grow at a CAGR of roughly 11.0% over the next five years, will reach 1590 million US$ in 2023, from 850 million US$ in 2017, according to a new study.
This report focuses on the Febuxostat in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers Takeda Pharmaceuticals
MACLEODS
Prinston Pharmaceutical
Alembic Pharmaceuticals
Hikma Pharmaceuticals
Lupin Limited
Mylan
Teijin Pharma
Hengrui Pharma
Sun Pharma
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers 40mg
80mg
20mg
120mg
Market Segment by Applications, can be divided into Acute Gout
Chronic Gout
There are 15 Chapters to deeply display the global Febuxostat market.
Chapter 1, to describe Febuxostat Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Febuxostat, with sales, revenue, and price of Febuxostat, in 2018 and 2019;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2018 and 2019;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Febuxostat, for each region, from 2015 to 2020;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;
Chapter 12, Febuxostat market forecast, by regions, type and application, with sales and revenue, from 2020 to 2026;
Chapter 13, 14 and 15, to describe Febuxostat sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
